tradingkey.logo
๎™

Tivic Health Systems Inc

TIVC
1.890USD
0.000
์ข…๊ฐ€ย 12/24, 13:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
3.14M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Tivic Health Systems Inc ํšŒ์‚ฌ

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.

Tivic Health Systems Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ TIVC
ํšŒ์‚ฌ ์ด๋ฆ„Tivic Health Systems Inc
์ƒ์žฅ์ผNov 11, 2021
CEOErnst (Jennifer)
์ง์› ์ˆ˜7
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒNov 11
์ฃผ์†Œ47685 Lakeview Blvd
๋„์‹œFREMONT
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ94538
์ „ํ™”18882766888
์›น์‚ฌ์ดํŠธhttps://tivichealth.com/
์ข…๋ชฉ ์ฝ”๋“œ TIVC
์ƒ์žฅ์ผNov 11, 2021
CEOErnst (Jennifer)

Tivic Health Systems Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Dec 24
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Dec 24
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Avenue Capital Group
5.76%
Statera BioPharma, Inc
3.47%
DRW Securities, LLC
3.05%
Avenue Venture Opportunities Fund LP
2.84%
Marex Group plc
2.17%
๊ธฐํƒ€
82.71%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Avenue Capital Group
5.76%
Statera BioPharma, Inc
3.47%
DRW Securities, LLC
3.05%
Avenue Venture Opportunities Fund LP
2.84%
Marex Group plc
2.17%
๊ธฐํƒ€
82.71%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Corporation
6.30%
Investment Advisor/Hedge Fund
6.04%
Investment Advisor
5.38%
Individual Investor
1.37%
Research Firm
0.08%
๊ธฐํƒ€
80.82%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
2023Q2
33
60.32K
19.16%
+13.93K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Statera BioPharma, Inc
61.20K
3.89%
+61.20K
--
May 14, 2025
Avenue Venture Opportunities Fund LP
50.13K
3.18%
+50.13K
--
May 14, 2025
Marex Group plc
39.28K
2.5%
+39.28K
--
Jun 30, 2025
Ernst (Jennifer)
23.25K
1.48%
+22.54K
+3192.78%
Sep 22, 2025
Geode Capital Management, L.L.C.
--
0%
-2.15K
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
5.65K
0.36%
+5.65K
--
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
์ด๋ฆ„
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
Mar 05, 2025
Merger
17โ†’1
Mar 05, 2025
Merger
17โ†’1
Mar 05, 2025
Merger
17โ†’1
Mar 05, 2025
Merger
17โ†’1
Aug 22, 2023
Merger
100โ†’1
Aug 22, 2023
Merger
100โ†’1
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
Mar 05, 2025
Merger
17โ†’1
Mar 05, 2025
Merger
17โ†’1
Mar 05, 2025
Merger
17โ†’1
Mar 05, 2025
Merger
17โ†’1
Aug 22, 2023
Merger
100โ†’1
Aug 22, 2023
Merger
100โ†’1
Aug 22, 2023
Merger
100โ†’1
Aug 22, 2023
Merger
100โ†’1

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Tivic Health Systems Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Tivic Health Systems Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Statera BioPharma, Inc๋Š” 61.20K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.89%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Avenue Venture Opportunities Fund LP๋Š” 50.13K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.18%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Marex Group plc๋Š” 39.28K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 2.50%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Ernst (Jennifer)๋Š” 23.25K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 1.48%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Geode Capital Management, L.L.C.๋Š” 0.00์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.00%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Tivic Health Systems Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Tivic Health Systems Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
Avenue Capital Group
Statera BioPharma, Inc
DRW Securities, LLC์ž…๋‹ˆ๋‹ค.

Tivic Health Systems Inc(TIVC)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q3 ๊ธฐ์ค€์œผ๋กœ, Tivic Health Systems Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 22๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 44.96K๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 2.86%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q2 ๋Œ€๋น„ -7.96% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Tivic Health Systems Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
-- ๊ธฐ์ค€, Tivic Health Systems Inc์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™